Researchers at The University of Texas MD Anderson Cancer Center reported cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy. Working in cell lines and mouse models of lung cancer, a team led by Don Gibbons, M.D., Ph.D., associate professor of Thoracic/Head & Neck Medical Oncology, demonstrated how the KRAS-driven lung cancer cells defeat treatment by switching from stable, stationary cells into a type of mobile, resistant cell associated with embryonic development. They also found a drug combination...

Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study from The University of Texas MD Anderson Cancer Center. The researchers believe the findings, published today in JAMA Internal Medicine, reinforce the need for including these risks in the shared decision-making communication between...

Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation. “Classical wisdom is that brain tumor progression is linked to oncogene activation and tumor suppressor gene inactivation; however genetic and epigenetic mutations are not the only cause of GBM progression,” said Shulin Li, Ph.D. “Some immune regulators can do the...

A large nationwide study led by The University of Texas Medical Branch at Galveston has confirmed that among various surgical procedures, removing sections of the colon carries the highest risk of complications and has a 46 percent mortality rate, despite efforts to improve surgical outcomes at large. Shining light on this issue can guide advances and improvements targeted directly toward this procedure. The American College of Surgeons works to improve the quality of surgeries throughout...

There is a new medication that in one dose successfully protected nonhuman primates against a lethal infection of all strains of the deadly Ebola virus. Dr. Thomas Geisbert, a world-renowned Ebola researcher at The University of Texas Medical Branch at Galveston, said that previous therapeutics typically were of the “one bug, one drug” variety. But because of the unpredictable nature and variety of the Ebola virus, scientists have been seeking a way to protect against...